Meeder Asset Management Inc Oncocyte Corp Transaction History

Meeder Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.76 - $15.98 $339 - $7,143	-447 Reduced 69.63%	195 $0
Q2 2022 Aug 08, 2022	SELL	$0.86 - $1.53 $102 - $182	-119 Reduced 15.64%	642 $0
Q1 2022 May 10, 2022	BUY	$1.15 - $2.25 $875 - $1,712	761 New	761 $1,000
Q4 2021 Feb 11, 2022	SELL	$2.04 - $3.59 $8,053 - $14,173	-3,948 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$3.77 - $6.0 $727 - $1,158	193 Added 5.14%	3,948 $23,000
Q1 2021 Apr 28, 2021	BUY	$2.39 - $6.5 $8,974 - $24,407	3,755 New	3,755 $20,000
Q4 2020 Feb 09, 2021	SELL	$1.38 - $2.63 $5,129 - $9,775	-3,717 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.76 - $3.02 $4,949 - $8,492	2,812 Added 310.72%	3,717 $9,000
Q4 2019 Feb 13, 2020	SELL	$1.51 - $2.27 $64 - $97	-43 Reduced 4.54%	905 $2,000
Q3 2019 Oct 17, 2019	BUY	$1.59 - $2.51 $1,507 - $2,379	948 New	948 $2,000
Q1 2018 May 03, 2018	SELL	$1.25 - $4.6 $12 - $46	-10 Closed	0 $0
Q4 2017 Feb 02, 2018	BUY	$3.9 - $7.4 $39 - $74	10	10 $0

1.5M

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $338M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.